## PRACTICAL FEASIBILITY ASSESSMENT
### Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
**Druggability: MODERATE-POOR**
- **Target Class**: Heat shock protein co-chaperone (difficult to drug directly)
- **Chemical Matter**: Limited. No known direct DNAJB6 activators exist
- **Existing Tools**:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
**Competitive Landscape:**
- **Direct competitors**: None targeting DNAJB6 specifically
- **Adjacent space**: Multiple HSP70/HSP90 programs (Orphazyme's arimoclomol failed in ALS)
- **Companies**: No major pharma programs identified
**Safety Concerns:**
- DNAJB6 mutations cause limb-girdle muscular dystrophy 1D
- Overexpression could disrupt proteostasis balance
- Potential cardiac toxicity (chaperones critical for cardiac function)
**Cost/Timeline Estimate:**
- **Discovery**: $15-25M, 4-5 years (need to identify druggable mechanism)
- **Total to clinic**: $50-80M, 7-10 years
- **Risk**: Very high - no validated approach to drug this target
---
### Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance
**Druggability: MODERATE**
- **Target Class**: Immune receptor (engineerable but complex)
- **Chemical Matter**:
- TREM2 agonist antibodies in development
- Small molecule TREM2 activators (early research)
- **Existing Tools**:
- AL002 (Alector) - TREM2 agonist antibody in Phase 2 for AD
- Anti-TREM2 antibodies for research
**Competitive Landscape:**
- **Active Programs**:
- Alector (AL002, AL101) - $300M+ invested
- Genentech collaboration with Alector
- Multiple academic programs on TREM2 modulation
**Safety Concerns:**
- Immune system modulation risks
- Potential for excessive neuroinflammation
- TREM2 variants associated with increased AD risk
**Cost/Timeline Estimate:**
- **Engineered approach**: $100-200M, 8-12 years
- **Antibody approach**: $80-150M, 6-10 years
- **Risk**: High - engineering specificity is unproven
---
### Hypothesis 3: Prohibitin-2 Cross-Seeding Hub Disruption
**Druggability: POOR**
- **Target Class**: Mitochondrial scaffold protein (very difficult)
- **Chemical Matter**: Virtually none targeting PHB2 specifically
- **Existing Tools**:
- General mitochondrial modulators (limited utility)
- No selective PHB2 modulators available
**Competitive Landscape:**
- **Direct competitors**: None
- **Mitochondrial space**: Multiple programs (Stealth BioTherapeutics, Khondrion - mostly failed)
**Safety Concerns:**
- PHB2 essential for mitochondrial integrity
- Potential cardiac and muscle toxicity
- Disrupting mitochondrial function could worsen neurodegeneration
**Cost/Timeline Estimate:**
- **Discovery**: $20-40M, 5-8 years (if druggable site found)
- **Major risk**: May be undruggable target
- **Likelihood of success**: <20%
---
### Hypothesis 4: RNA-Binding Competition Therapy
**Druggability: POOR-MODERATE**
- **Target Class**: RNA-protein interaction (challenging but emerging)
- **Chemical Matter**:
- RNA aptamers (delivery challenges)
- Small molecules targeting RNA-binding domains (limited success)
- **Existing Tools**:
- Research-grade TDP-43 RNA aptamers
- Antisense oligonucleotides (ASOs) for related targets
**Competitive Landscape:**
- **RNA space**: Ionis, Alnylam, others (focused on different mechanisms)
- **TDP-43**: Wave Life Sciences (WVE-004 ASO failed), no major current programs
- **Limited competitive pressure**
**Safety Concerns:**
- TDP-43 essential for normal RNA processing
- Potential for widespread cellular dysfunction
- CNS delivery challenges for RNA therapeutics
**Cost/Timeline Estimate:**
- **ASO approach**: $80-120M, 6-9 years
- **Aptamer approach**: $60-100M, 8-12 years
- **Risk**: Very high due to delivery and specificity issues
---
### Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition
**Druggability: MODERATE-GOOD**
- **Target Class**: Enzyme (generally druggable)
- **Chemical Matter**:
- Irreversible inhibitors: cysteamine, cystamine
- Reversible inhibitors: GK921, ZED1227
- **Existing Tools**:
- **ZED1227** (Zedira) - selective TG2 inhibitor, Phase 2a for celiac disease
- **ERW1227** - TG2 inhibitor for fibrosis
**Competitive Landscape:**
- **Active Programs**:
- Zedira (ZED1227) - most advanced
- Academic programs for neurodegeneration
- Limited competition in CNS space
**Safety Concerns:**
- TG2 important for wound healing, apoptosis
- Potential bleeding/clotting issues
- GI side effects observed with inhibitors
**Cost/Timeline Estimate:**
- **Existing inhibitor**: $40-80M, 4-6 years (repurposing ZED1227)
- **New inhibitor**: $60-120M, 6-9 years
- **Risk**: Moderate - established druggable target
---
### Hypothesis 6: Liquid-Liquid Phase Separation Modifier
**Druggability: POOR-MODERATE**
- **Target Class**: Physical chemistry modulators (novel, challenging)
- **Chemical Matter**:
- 1,6-hexanediol (research tool, toxic)
- Antisense against stress granule components
- **Existing Tools**:
- Research compounds only
- No validated therapeutic approaches
**Competitive Landscape:**
- **Emerging field**: No major pharma programs
- **Academic interest**: High but early stage
- **Opportunity**: First-in-class potential
**Safety Concerns:**
- Phase separation essential for cellular function
- Potential widespread cellular toxicity
- Unknown long-term effects
**Cost/Timeline Estimate:**
- **Discovery**: $30-60M, 5-8 years (high uncertainty)
- **Risk**: Very high - novel mechanism, unclear path forward
---
### Hypothesis 7: Glycosaminoglycan Template Disruption
**Druggability: MODERATE**
- **Target Class**: Glycosaminoglycans (some precedent)
- **Chemical Matter**:
- Heparanase inhibitors: OGT2115, PG545
- GAG mimetics: PI-88, M402
- **Existing Tools**:
- **OGT2115** (Oncogene Therapeutics) - heparanase inhibitor
- **PG545** (Zucero Therapeutics) - heparan sulfate mimetic
**Competitive Landscape:**
- **Cancer programs**: Multiple (Oncogene, Zucero, others)
- **CNS programs**: Limited activity
- **Delivery challenge**: Major barrier for all players
**Safety Concerns:**
- GAGs essential for development, signaling
- Anticoagulant effects possible
- Limited CNS penetration
**Cost/Timeline Estimate:**
- **Repurposing**: $50-100M, 5-8 years
- **New development**: $80-150M, 7-10 years
- **Risk**: Moderate-high due to delivery challenges
---
## OVERALL ASSESSMENT RANKING
**Most Feasible (Descending Order):**
1. **TG2 Inhibition** - Established target, existing compounds, moderate risk
2. **GAG Disruption** - Some precedent, existing tools, delivery challenges
3. **TREM2 Engineering** - Active field, high investment, engineering risk
4. **DNAJB6 Activation** - Novel but difficult target, no validated approach
5. **Phase Separation** - Novel field, unclear druggability
6. **RNA Competition** - Delivery and specificity challenges
7. **Prohibitin-2** - Likely undruggable, essential function
**RECOMMENDED PRIORITY**: Focus resources on TG2 inhibition with ZED1227 repurposing - lowest risk, fastest timeline, established safety profile.